<table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="tbl3" position="float"><object-id pub-id-type="doi">10.7554/eLife.19352.014</object-id><label>Table 3.</label><caption><p>Investigation of mechanisms involved in postictal severe hypoxia.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.19352.014">http://dx.doi.org/10.7554/eLife.19352.014</ext-link></p></caption><table frame="hsides" rules="groups"><thead><tr><th><p><bold>Drug</bold></p> </th><th><p><bold>Principle known mechanism of action</bold></p> </th><th valign="top"><p><bold>&#916; severity of hypoxia</bold><inline-formula><mml:math id="inf1"><mml:mrow><mml:mfrac><mml:mrow><mml:mo>(</mml:mo><mml:mstyle mathsize="normal" mathvariant="bold"><mml:mi>V</mml:mi><mml:mi>e</mml:mi><mml:mi>h</mml:mi></mml:mstyle><mml:mo>&#8722;</mml:mo><mml:mstyle mathsize="normal" mathvariant="bold"><mml:mi>D</mml:mi><mml:mi>r</mml:mi><mml:mi>u</mml:mi><mml:mi>g</mml:mi></mml:mstyle><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mstyle mathsize="normal" mathvariant="bold"><mml:mi>V</mml:mi><mml:mi>e</mml:mi><mml:mi>h</mml:mi></mml:mstyle></mml:mrow></mml:mfrac><mml:mo>&#160;</mml:mo><mml:mo>&#215;</mml:mo><mml:mo>&#160;</mml:mo><mml:mn>100</mml:mn><mml:mi>%</mml:mi></mml:mrow></mml:math></inline-formula></p></th></tr></thead><tbody><tr><td valign="top"><p>Nifedipine (15 mg/kg)</p></td><td rowspan="2" valign="top"><p>L-type Ca<sup>2+</sup> Channel Blocker</p></td><td valign="top"><p>+78.82&#160;&#177;&#160;7.632% ***</p></td></tr><tr><td valign="top"><p>Nifedipine (15 mg/kg postictal)</p></td><td><p>+87.33&#160;&#177;&#160;10.49% **</p></td></tr><tr><td valign="top"><p>Acetaminophen (250 mg/kg)</p></td><td rowspan="5"><p>COX-1/2 Inhibitor</p></td><td valign="top"><p>+99.88&#160;&#177;&#160;0.12% ***</p></td></tr><tr><td valign="top"><p>Acetaminophen (150 mg/kg)</p></td><td valign="top"><p>+88.88&#160;&#177;&#160;7.355% ***</p></td></tr><tr><td valign="top"><p>Acetaminophen (50 mg/kg)</p></td><td valign="top"><p>+48.85&#160;&#177;&#160;26.61%</p> </td></tr><tr><td valign="top"><p>Acetaminophen (250 mg/kg postictal)</p></td><td><p>&#8722;3.33&#160;&#177;&#160;17.29%</p> </td></tr><tr><td valign="top"><p>Ibuprofen (20 mg/kg)</p></td><td valign="top"><p>+99.23&#160;&#177;&#160;0.396% ***</p></td></tr><tr><td valign="top"><p>Celecoxib (20 mg/kg)</p></td><td valign="top"><p>COX-2 Inhibitor</p></td><td valign="top"><p>+67.26&#160;&#177;&#160;27.42% *</p></td></tr><tr><td valign="top"><p>SC-560 (20 mg/kg)</p></td><td valign="top"><p>COX-1 Inhibitor</p></td><td valign="top"><p>+19.42&#160;&#177;&#160;15.37%</p> </td></tr><tr><td valign="top"><p>Celecoxib (20 mg/kg) + SC-560 (20 mg/kg)</p></td><td><p>COX-2 and COX-1 Inhibitors</p></td><td><p>+95.80&#160;&#177;&#160;4.21% ***</p></td></tr><tr><td valign="top"><p>Acetaminophen (250 mg/kg) + Nifedipine (15 mg/kg)</p></td><td valign="top"><p>COX-1/2 Inhibitor + L-type Ca<sup>2+</sup> Channel Blocker</p></td><td><p>+100&#160;&#177;&#160;0.00% ***</p></td></tr><tr><td><p>CAY-10526 (2 mg/kg)</p></td><td valign="top"><p>Prostaglandin E2 Synthesis Inhibitor</p></td><td><p>+41.72&#160;&#177;&#160;9.94% **</p></td></tr><tr><td><p>Seratrodast (10 mg/kg)</p></td><td valign="top"><p>Thromboxane A2 Receptor Antagonist</p></td><td><p>&#8722;12.91&#160;&#177;&#160;44.08%</p> </td></tr><tr><td><p>Ozagrel (10 mg/kg)</p></td><td valign="top"><p>Thromboxane A2 Synthesis Inhibitor</p></td><td><p>+21.24&#160;&#177;&#160;16.42%</p> </td></tr><tr><td><p>2-APB (3 mg/kg)</p></td><td valign="top"><p>IP3r Antagonist + TRP Channel Blocker</p></td><td><p>+45.27&#160;&#177;&#160;18.44% *</p></td></tr><tr><td valign="top"><p>Chelerythrine Chloride (15 mg/kg)</p></td><td><p>PKC Inhibitor</p></td><td><p>+25.54&#160;&#177;&#160;29.90%</p> </td></tr><tr><td valign="top"><p>Milrinone (3 mg/kg)</p></td><td valign="top"><p>Phosphodiesterase-3 Inhibitor</p></td><td valign="top"><p>&#8722;10.74&#160;&#177;&#160;34.31%</p> </td></tr><tr><td valign="top"><p>Sildenafil (15 mg/kg)</p></td><td valign="top"><p>Phosphodiesterase-5 Inhibitor</p></td><td valign="top"><p>&#8722;19.34&#160;&#177;&#160;14.03%</p> </td></tr><tr><td valign="top"><p>SKA-31 (10 mg/kg)</p></td><td valign="top"><p>IK<sub>Ca</sub> Channel Activator</p></td><td valign="top"><p>&#8722;1.50&#160;&#177;&#160;12.68%</p> </td></tr><tr><td valign="top"><p>Paxilline (2.5 mg/kg)</p></td><td valign="top"><p>BK<sub>Ca</sub> Channel Blocker</p></td><td valign="top"><p>+19.55&#160;&#177;&#160;14.98%</p> </td></tr><tr><td valign="top"><p>L-Arginine (500 mg/kg)</p></td><td valign="top"><p>Nitric Oxide Precursor</p></td><td valign="top"><p>&#8722;5.05&#160;&#177;&#160;14.08%</p> </td></tr><tr><td valign="top"><p>Fasudil (10 mg/kg)</p></td><td valign="top"><p>Rho Kinase Inhibitor</p></td><td valign="top"><p>&#8722;53.07&#160;&#177;&#160;17.27% *</p></td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><p>All drugs were delivered by intraperitoneal injection pre-seizure (unless otherwise stated).</p></fn><fn id="tblfn2"><p>Statistics reported as different from chance (one sample T-test).</p></fn><fn id="tblfn3"><p>*p&#160;&lt;&#160;0.05, **p&lt;0.01, ***p&lt;0.001.</p></fn><fn id="tblfn4"><p>+ number indicates inhibition of hypoxia.</p></fn><fn id="tblfn5"><p>&#8722; number indicates potentiation of hypoxia.</p></fn></table-wrap-foot></table-wrap>